A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 1,401–1,500 of 3,965
Wu, C., Or, P. W., Chong, J. I. T., don, I. K. K. P., Lee, C. H. C., Wu, K., Yu, M., LAM, D. C. C., & Yang, Y. (2021) · Drug Delivery · doi:10.1080/10717544.2021.1895911 · Cited by 28
Dempsey, T. M., Thao, V., Moriarty, J. P., Borah, B. J., & LIMPER, A. H. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01811-0 · Cited by 25
Risk Factors of Silicosis Progression: A Retrospective Cohort Study in China
Quan, H., Wu, W., Yang, G., Wu, Y., Yang, W., Min, C. Y., Shi, J., Qin, L., Huang, J., Wang, J., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.832052 · Cited by 32
Khor, Y. H., Farooqi, M. A., Hambly, N., Johannson, K. A., Marcoux, V. S., Fisher, J. H., Assayag, D., Manganas, H., Khalil, N., Kolb, M., et al. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.08.2233 · Cited by 32
Walking the path of treatable traits in interstitial lung diseases
Amati, F., Spagnolo, P., Ryerson, C. J., Oldham, J. M., Gramegna, A., Stainer, A., Mantero, M., Sverzellati, N., Lacedonia, D., Richeldi, L., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02554-8 · Cited by 24
Huh, J.-Y., Lee, J. H., & Song, J. W. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1301923 · Cited by 31
Devaraj, A., Ottink, F. A., Rennison-Jones, C., Blé, F.-X., Joly, O., Azim, A., Gerry, S., Harston, G., Ostridge, K., & George, P. M. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202312-2274le · Cited by 29
Identifying Mechanisms of Homeostatic Signaling in Fibroblast Differentiation
Warsinske, H., Ashley, S. L., Linderman, J. J., Moore, B. B., & Kirschner, D. E. (2015) · Bulletin of Mathematical Biology · doi:10.1007/s11538-015-0096-2 · Cited by 26
“Idiopathic pulmonary fibrosis (IPF), for example, results in decreased inspiration and expiration capacity and has an average prognosis of 2– 4years (Ley et al. 2011; Taniguchi et al. 2011; King et al. 2014; Richeldi et al. 2014; Xaubet et al. 2014).”
Fernandez, I. E., Heinzelmann, K., Verleden, S. E., & Eickelberg, O. (2015) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201410-476mg · Cited by 24
Zakrzewicz, D., Zakrzewicz, A., Didiášová, M., Korencak, M., Kosanovic, D., SCHERMULY, R. T., Markart, P., & Wygrecka, M. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.09.008 · Cited by 26
Fernandez, I. E., Amarie, O. V., Mutze, K., Königshoff, M., Yildirim, A. Ö., & Eickelberg, O. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00183.2015 · Cited by 28
Lian, X., Chen, X., Sun, J., An, G., Li, X., Wang, Y., Niu, P., Zhu, Z., & Tian, L. (2017) · Toxicology Research · doi:10.1039/c7tx00126f · Cited by 24
Johannson, K. A., Kolb, M. R. J., Fell, C. D., Assayag, D., Fisher, J. H., Churg, A., de Boer, K., Kelly, M. M., Lee, A. G., Leipsic, J. A., et al. (2017) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2017.1359056 · Cited by 23
Pan, L., Belloni, P., Ding, H. T., Wang, J., Rubino, C. M., & Putnam, W. S. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0594-8 · Cited by 23
Manitsopoulos, N., Nikitopoulou, I., Maniatis, N. A., Μagkou, C., Kotanidou, A. N., & Orfanos, S. E. (2017) · Respiration · doi:10.1159/000481201 · Cited by 25
Magnani, D., Lenoci, G., Balduzzi, S., Artioli, G., & Ferri, P. (2017) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v88i5-s.6870 · Cited by 25
Kokosi, M. A., Margaritopoulos, G. A., & Wells, A. U. (2018) · European Respiratory Review · doi:10.1183/16000617.0117-2017 · Cited by 27
Visual analogue scales for interstitial lung disease: a prospective validation study
Yates, H., Adamali, H. I., Maskell, N. A., Barratt, S. L., & Sharp, C. (2018) · QJM · doi:10.1093/qjmed/hcy102 · Cited by 28
Targeting an oncogenic kinase/phosphatase signaling network for cancer therapy
Qi, X.-M., Wang, F., Mortensen, M., Wertz, R., & Chen, G. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.05.007 · Cited by 23
Kanemaru, R., Takahashi, F., Kato, M., Mitsuishi, Y., Tajima, K., Ihara, H., Hidayat, M., Wirawan, A., Koinuma, Y., Hayakawa, D., et al. (2018) · Lung · doi:10.1007/s00408-018-0134-6 · Cited by 26
“In the pathogenesis of IPF, a possible role of TGFβ is to induce EMT in alveolar epithelial cells, and cells that have undergone EMT would contribute to the formation of fibroblastic foci and to abnormal ECM accumulation [25, 26] Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series.”
BackgroundInfluentialSköld, C. M., Arnheim‐Dahlström, L., Bartley, K., Janson, C., Kirchgaessler, K.-U., LEVINE, A. M., & Ferrara, G. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2019.06.001 · Cited by 26
Morisset, J., & Lee, J. S. (2019) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000600 · Cited by 23
Milara, J., Ballester, B., Safont, M. J., Artigues, E., Escrivá, J., Morcillo, E. J., & Cortijo, J. (2020) · Mucosal Immunology · doi:10.1038/s41385-020-00343-w · Cited by 24
The Protective Effects of IL-31RA Deficiency During Bleomycin-Induced Pulmonary Fibrosis
Yombo, D. J. K., Odayar, V., Gupta, N., Jegga, A. G., & Madala, S. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.645717 · Cited by 22
“Currently, the United States Food and Drug Administration (FDA) approved therapies to treat IPF, Nintedanib or Pirfenidone, slow the rate of FVC decline but do not reverse ongoing fibrosis (3, 4).”
BackgroundPulmonary rehabilitation in patients with interstitial lung diseases: Correlates of success
Brunetti, G., Malovini, A. L., Maniscalco, M., Balestrino, A., Carone, M., Visca, D., Capelli, A., Vitacca, M., Bellazzi, R., Piaggi, G., et al. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106473 · Cited by 24
Cottin, V., Bonniaud, P., Cadranel, J. L., Crestani, B., Jouneau, S., Marchand-Adam, S., Nunès, H., Wémeau-Stervinou, L., Bergot, E., Blanchard, É., et al. (2022) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2022.01.005 · Cited by 27
Guidelines or guidance for better idiopathic pulmonary fibrosis management?
Behr, J. (2016) · BMC Medicine · doi:10.1186/s12916-016-0567-9 · Cited by 22
For the CleanUP-IPF Study Team, Anstrom, K. J., Noth, I., Flaherty, K. R., Edwards, R., Albright, J., Baucom, A., Brooks, M. M., Clark, A., Clausen, E. S., et al. (2020) · Respiratory Research · doi:10.1186/s12931-020-1326-1 · Cited by 26
Drug-induced interstitial lung disease: a narrative review of a clinical conundrum
Harrison, M. L., Kavanagh, G., Corte, T. J., & Troy, L. K. (2024) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2024.2329612 · Cited by 28
Macisaac, S., Somboonviboon, D., Scallan, C. J., & Kolb, M. R. J. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2340723 · Cited by 28
Zou, Y., Dai, J., Li, J., Liu, M., Li, R., Li, G., Lai, J., & Wang, L. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5603 · Cited by 30
Ahidjo, B. A., Maiga, M. C., Ihms, E. A., Maïga, M., Ordoñez, A. A., Cheung, L. S., Beck, S. E., Andrade, B. B., Jain, S. K., & Bishai, W. R. (2016) · JCI Insight · doi:10.1172/jci.insight.86017 · Cited by 22
Cottin, V., Crestani, B., Cadranel, J. L., Cordier, J. F., Marchand-Adam, S., Prévot, G., Wallaert, B., Bergot, E., Camus, P., Dalphin, J., et al. (2017) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2017.07.018 · Cited by 25
Zhang, J., Li, Q., Shao, Q., Song, J., Zhou, B., & Shu, P. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27045 · Cited by 22
Cell Therapy in Idiopathic Pulmonary Fibrosis†
Serrano‐Mollar, A. (2018) · Medical Sciences · doi:10.3390/medsci6030064 · Cited by 27
Lai, R.-S., Chen, C.-F., Chu, K., & Lin, M. (2019) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000201 · Cited by 22
Aronson, K. I., Hayward, B. J., Robbins, L. P., Kaner, R. J., Martínez, F. J., & Safford, M. M. (2019) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2019-000522 · Cited by 24
Nakanishi, T., Cerani, A., Forgetta, V., Zhou, S., Allen, R. J., Leavy, O. C., Koido, M., Assayag, D., Jenkins, G. R., Wain, L. V., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.03979-2020 · Cited by 22
Solomon, J. J., Swigris, J. J., Kreuter, M., Polke, M., Aronson, K. I., Hoffmann‐Vold, A., & Dellaripa, P. F. (2021) · Rheumatology · doi:10.1093/rheumatology/keab552 · Cited by 24
Self-citationKhor, Y. H., Goh, N. S. L., Wong, A. W., Johannson, K. A., Marcoux, V. S., Fisher, J. H., Assayag, D., Manganas, H., Khalil, N., Kolb, M. R. J., et al. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202108-980oc · Cited by 23
Yang, X., Sun, W., Jing, X., Zhang, Q., Huang, H. F., & Xu, Z. (2022) · Respiratory Research · doi:10.1186/s12931-022-02012-x · Cited by 24
Hung, C., Tsai, Y.-W., Wu, Y., Yeh, C., & Yang, K. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00850-x · Cited by 23
Doi, H., Atsumi, J., Baratz, D. M., & Miyamoto, Y. (2023) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2023.0014 · Cited by 25
Wang, X., Wan, W., Zhang, J., Lü, J., & Liu, P. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.042 · Cited by 23
Bridges, J. F. P., Paly, V. F., Barker, E. R., & Kervitsky, D. J. (2014) · Patient · doi:10.1007/s40271-014-0081-0 · Cited by 27
Zhou, W., Zhuang, Y., Sun, J., Wang, X., Zhao, Q., Xu, L., & Wang, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-04486-y · Cited by 22
C-proSP-B: A Possible Biomarker for Pulmonary Diseases?
Kahn, N. C., Rossler, A.-K., Hornemann, K., Muley, T., Grünig, E., Schmidt, W. W., Herth, F. J. F., & Kreuter, M. (2018) · Respiration · doi:10.1159/000488245 · Cited by 22
Diagnosing complications and co-morbidities of fibrotic interstitial lung disease
Margaritopoulos, G. A., Kokosi, M. A., & Wells, A. U. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1632196 · Cited by 25
Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update
Wongkarnjana, A., Yanagihara, T., & Kolb, M. R. J. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1673733 · Cited by 25
Smith, M. L., Hariri, L. P., Mino-Kenudson, M. A., Đačić, S., Attanoos, R. L., Borczuk, A., Colby, T. V., Cooper, W. A., Jones, K. D., Leslie, K. O., et al. (2020) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2020-0052-ra · Cited by 24
Singh, V., Singh, S., Sharma, B., Bairwa, M. L., Gothi, D., Desai, U. D., Joshi, J. M., Talwar, D., Singh, A., Dhar, R., et al. (2020) · Lung India · doi:10.4103/lungindia.lungindia_275_20 · Cited by 25
Antibody-mediated depletion of CCR10+EphA3+ cells ameliorates fibrosis in IPF
Hohmann, M. S., Habiel, D. M., Espíndola, M. S., Huang, G., Jones, I. C., Narayanan, R., Coelho, A. L., Oldham, J. M., Noth, I., Ma, S., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.141061 · Cited by 23
Self-citationHuang, T., Kuo, C., Chen, C., Tseng, Y., Wu, C., & Lin, S. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01530-6 · Cited by 25
Proteomic Biomarkers of Quantitative Interstitial Abnormalities in COPDGene and CARDIA Lung Study
Choi, B., Liu, G. Y., Sheng, Q., Amancherla, K. V., Perry, A., Huang, X., Estépar, R. S. J., Ash, S. Y., Guan, W., Jacobs, D. R., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202307-1129oc · Cited by 21
Tu, M., Lu, C., Jia, H., Chen, S., Wang, Y., Li, J., Cheng, J., Yang, M., & Zhang, G. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05698-3 · Cited by 24
Hagmeyer, L., Treml, M., Priegnitz, C., & Randerath, W. J. (2016) · Respiration · doi:10.1159/000444690 · Cited by 22
Cytokine and anti-cytokine therapies in prevention or treatment of fibrosis in IBD
Jacob, N., Targan, S. R., & Shih, D. Q. (2016) · United European Gastroenterology Journal · doi:10.1177/2050640616649356 · Cited by 53
New insights on patient-reported outcome measures in idiopathic pulmonary fibrosis: only PROMises?
Wijsenbeek, M. S., van Manen, M. J. G., & Bonella, F. (2016) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000294 · Cited by 24
Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
Glassberg, M. K., Wijsenbeek, M. S., Gilberg, F., Petzinger, U., Kirchgaessler, K.-U., & Albera, C. (2019) · European Respiratory Journal · doi:10.1183/13993003.00399-2019 · Cited by 23
Self-citationDerseh, H. B., Dewage, S. N. V., Perera, K. U. E., Pagel, C. N., Koumoundouros, E., Organ, L. A., & Snibson, K. J. (2019) · Scientific Reports · doi:10.1038/s41598-019-56412-z · Cited by 21
Familial Interstitial Lung Disease
Kropski, J. A. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0040-1708054 · Cited by 23
Nonspecific Interstitial Pneumonia
Teoh, A. K. Y., & Corte, T. J. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0040-1708499 · Cited by 28
Noor, S., Nawaz, S., & Chaudhuri, N. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01523-7 · Cited by 26
Chen, T., Tsai, A. P. Y., Hur, S. A., Wong, A. W., Sadatsafavi, M., Fisher, J. H., Johannson, K. A., Assayag, D., Morisset, J., Shapera, S., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01790-0 · Cited by 26
Ebrahimpour, A., Wang, M., Li, L., Jegga, A. G., Bonnen, M., Eissa, N. T., Raghu, G., Jyothula, S., Kheradmand, F., Hanania, N. A., et al. (2021) · Journal of Inflammation · doi:10.1186/s12950-021-00284-6 · Cited by 22
IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis
Nakanishi, Y., Horimasu, Y., Yamaguchi, K., Sakamoto, S., Masuda, T., Nakashima, T., Miyamoto, S., Iwamoto, H., Ohshimo, S., Fujitaka, K., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252594 · Cited by 22
Chronic Lung Allograft Dysfunction
Venado, A. E., Kukreja, J., & Greenland, J. R. (2022) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2021.11.004 · Cited by 23
Application of Fluorescent Probes in Reactive Oxygen Species Disease Model
Niu, P., Zhu, J., Wei, L., & Liu, X. (2022) · Critical Reviews in Analytical Chemistry · doi:10.1080/10408347.2022.2080495 · Cited by 23
Idiopathic pulmonary fibrosis: Diagnosis, biomarkers and newer treatment protocols
Patel, H., Shah, J. R., Patel, D., Avanthika, C., Jhaveri, S., & Gor, K. (2022) · Disease-a-Month · doi:10.1016/j.disamonth.2022.101484 · Cited by 25
Behr, J., Bonella, F., Frye, B. C., Günther, A., Hagmeyer, L., Henes, J. C., Klemm, P., Koschel, D., Kreuter, M., Leuschner, G., et al. (2023) · Pneumologie · doi:10.1055/a-1983-6796 · Cited by 26
“für die 6-Minuten-Gehstrecke, das progressionsfreie Überleben und reduzierte die Mortalität numerisch, wenn auch nicht signifikant (HR 0,55; KI 0,26–1,15; p=0,10) [58].”
BackgroundInfluentialNam, J. G., Choi, Y., Lee, S., Yoon, S. H., Goo, J. M., & Kim, H. (2023) · European Radiology · doi:10.1007/s00330-023-09534-y · Cited by 23
Pharmacological approaches to pulmonary fibrosis following COVID-19
Laššán, Š., Tesař, T., Tisonova, J., & Laššánová, M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1143158 · Cited by 24
“In patients with IPF, pirfenidone at a daily dose of 2403 mg significantly reduced the rate of decline in forced vital capacity (FVC) (Lederer and Martinez. 2018; Noble et al., 2011; King et al., 2014) and improved survival.”
BackgroundTreatment strategies for idiopathic interstitial pneumonias
Wells, A. U., Kokosi, M. A., & Karagiannis, K. (2014) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000085 · Cited by 23
Defining, Treating, and Understanding Chronic Kidney Disease—A Complex Disorder
Campbell, D., & Weir, M. R. (2015) · Journal of Clinical Hypertension · doi:10.1111/jch.12560 · Cited by 24
Lim, H.-J., Chung, M. J., Shin, K. E., Hwang, H. S., & Lee, K. S. (2016) · Korean Journal of Radiology · doi:10.3348/kjr.2016.17.6.950 · Cited by 22
Novel form of miR-29b suppresses bleomycin-induced pulmonary fibrosis
Yamada, Y., Takanashi, M., Sudo, K., Ueda, S., Ohno, S., & Kuroda, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171957 · Cited by 22
Time for an International Consensus on Hypersensitivity Pneumonitis. A Call to Arms
Molyneaux, P. L., & Maher, T. M. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201707-1439ed · Cited by 21
Potential treatment for vocal fold scar with pirfenidone
Kodama, H., Kumai, Y., Nishimoto, K., Toya, Y., Miyamaru, S., Furushima, S., & Yumoto, E. (2017) · The Laryngoscope · doi:10.1002/lary.26999 · Cited by 21
Unfavourable outcome of glucocorticoid treatment in suspected idiopathic pulmonary fibrosis
Wiertz, I. A., Wuyts, W. A., van Moorsel, C. H. M., Vorselaars, A. D. M., van Es, H. W., van Oosterhout, M. F. M., & Grutters, J. C. (2017) · Respirology · doi:10.1111/resp.13230 · Cited by 24
Lacy, S. H., Epa, A. P., Pollock, S. J., Woeller, C. F., Thatcher, T. H., Phipps, R. P., & Sime, P. J. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00565.2016 · Cited by 24
Targeting the Myofibroblast in Pulmonary Fibrosis
Misharin, A. V., & Budinger, G. R. S. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201806-1037ed · Cited by 24
Ronan, N. J., Bennett, D. M., Khan, K. A., McCarthy, Y., Dahly, D. L., Bourke, L., Chelliah, A., Cavazza, A., O'Regan, K. N., Moloney, F., et al. (2018) · Lung · doi:10.1007/s00408-018-0140-8 · Cited by 22
Cocconcelli, E., Balestro, E., Biondini, D., Barbiero, G., Polverosi, R., Calabrese, F., Pezzuto, F., Lacedonia, D., Rea, F., Schiavon, M., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030399 · Cited by 24
“Due to the availability of effective anti-fibrotic drugs [30,31], studies on IPF patients naïve of antifibrotics will become progressively less common, if at all possible (and ethical).”
BackgroundSakayori, M., Terada, J., Abe, M., Hirasawa, Y., Suzuki, K., Yoshioka, K., Tsushima, K., & Tatsumi, K. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s208733 · Cited by 25
Qiu, Z., He, J., Zhang, H., et al. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116666 · Cited by 21
Fusco, R., Siracusa, R., D’Amico, R., Cordaro, M., Genovese, T., Gugliandolo, E., Peritore, A. F., Crupi, R., Paola, R. D., Cuzzocrea, S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207761 · Cited by 23
“tissue repair has positive effects on the histological alteration induced by pathology, but prolonged connective tissue deposition produces scarring, fibrosis and loss of organ functionality [4].”
BackgroundRetractedRaimundo, S., Pimenta, A. C., Martins, N. A., Rodrigues, M. C., Melo, N., Mota, P. C., Sokhatska, O., Bastos, H. N., Beltrão, M., Guimarães, S., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119274 · Cited by 22
NOX4 regulates macrophage apoptosis resistance to induce fibrotic progression
Larson‐Casey, J. L., Gu, L., Kang, J., Dhyani, A., & Carter, A. B. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100810 · Cited by 26
Novedades diagnósticas y terapéuticas en fibrosis pulmonar progresiva
Molina‐Molina, M., Buendía-Roldán, I., Castillo, D., Caro, F. M., Valenzuela, C., & Selman, M. (2022) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2021.12.006 · Cited by 25
A new approach based on CXCR4-targeted combination liposomes for the treatment of liver fibrosis
Ullah, A., Chen, G., Zhang, Y., Hussain, A., Shafiq, M., Raza, F., Liu, D., Wang, K., Cao, J., & Qi, X. (2022) · Biomaterials Science · doi:10.1039/d2bm00242f · Cited by 22
Genotype-Phenotype Associations of IL6 and PRG4 With Conjunctival Fibrosis After Glaucoma Surgery
Yu‐Wai‐Man, C., Tagalakis, A. D., Meng, J., Bouremel, Y., Lee, R. M. H., Virasami, A. K., Hart, S. L., & Khaw, P. T. (2017) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2017.3407 · Cited by 22
Chen, Z. B., Yun, X., Tian, J., Li, F., Zhang, Z., Meng, J., Li, N., Bian, H., Duan, S., & Zhang, L. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202403227 · Cited by 26
The role of macrophages in asthma-related fibrosis and remodelling
Yang, X., Li, F., Zhang, G., Foster, P. S., & Yang, M. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108820 · Cited by 23
Advances in idiopathic pulmonary fibrosis diagnosis and treatment
Liu, H., Shen, J., & He, C. (2025) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2025.02.001 · Cited by 23
Cordeiro, C. R., Campos, P., Carvalho, L., Borba, A., Clemente, S., Freitas, S., Furtado, S. T., Jesus, J. M., Leal, C., Marqués, J., et al. (2017) · Revista Portuguesa de Pneumologia · doi:10.1016/j.rppnen.2017.05.005 · Cited by 23
Post‐translational regulation of PGC‐1α modulates fibrotic repair
Larson‐Casey, J. L., Gu, L., Davis, D., Cai, G., Ding, Q., He, C., & Carter, A. B. (2021) · The FASEB Journal · doi:10.1096/fj.202100339r · Cited by 24
Lee, E. G., Lee, T.-H., Hong, Y., Ryoo, J., Heo, J. W., Gil, B. M., Kang, H. S., Kwon, S. S., & Kim, Y. H. (2021) · PLoS ONE · doi:10.1371/journal.pone.0261684 · Cited by 25
Jalbert, A.-C., Siafa, L., Ramanakumar, A. V., & Assayag, D. (2022) · European Respiratory Journal · doi:10.1183/13993003.02969-2021 · Cited by 20
CRTH2 Mediates Profibrotic Macrophage Differentiation and Promotes Lung Fibrosis
Cao, Y., Rudrakshala, J., Williams, R., Rodriguez, S., Sorkhdini, P., Yang, A. X., Mundy, M. A., Yang, D., Palmisciano, A. J., Walsh, T. P., et al. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2021-0504oc · Cited by 25
Chung, C., Kim, J., Cho, H. S., & Kim, H. C. (2022) · Scientific Reports · doi:10.1038/s41598-022-12399-8 · Cited by 27
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.